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Objective: Glucosamine is commonly used for the treatment of osteoarthritis. It is available as an over the
counter preparation and also as a prescription pharmaceutical. There is concern from animal experi-
ments that glucosamine may alter glucose metabolism through the hexosamine biosynthetic pathway.
The objective of this systematic review is to determine if exogenous glucosamine adversely affects
glucose metabolism in humans. This review does not separate out the effects on glucose metabolism of
the various glucosamine preparations.
Method: An English-language literature search of MEDLINE, EMBASE and EBM Reviews (1950eFebruary
2009) was conducted. The bibliographies of selected papers were manually searched for additional
references. Two reviewers independently analyzed studies for quality and content using a standardized
data extraction form.
Results: Eleven studies were included. Six studies were randomized controlled trials and the remaining
ﬁve were prospective studies with or without controls. Four of the studies found decreased insulin
sensitivity or increased fasting glucose in subjects taking glucosamine. Three of these were clinical
studies using oral glucosamine. Studies that included subjects with baseline impaired glucose tolerance
or insulin resistance were more likely to detect an effect on glucose metabolism than studies without
such subjects.
Conclusion: Clinical studies, including three using oral glucosamine, have provided mixed evidence about
the effect of exogenous glucosamine on glucose metabolism in humans. Therefore, more studies are
needed, particularly including subjects at high risk for impairments in glucose homeostasis, before
a deﬁnite conclusion can be made.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Glucosamine is a popular and widely used treatment for oste-
oarthritis (OA). It is available as an over the counter nutraceutical in
several countries and it is also available as a prescription pharma-
ceutical in Europe1. In the United States, glucosamine is used by
over ﬁve million people annually, making it the fourth most
commonly used herbal/dietary supplement2,3.
Glucosamine is considered to be very safe. A recent Cochrane
review (last updated in January 2008) found it to be as safe as
placebo1 and there have been no fatal or serious adverse effects
reported for oral glucosamine4. Additionally, there were no: Tanveer E. Towheed, Room
Ontario, Canada K7L3N6.
d).
s Research Society International. Psigniﬁcant differences in safety between the two most common
preparations, glucosamine sulfate and glucosamine hydrochloride1.
However, there is concern that glucosamine adversely affects
glucosemetabolism and causes insulin resistance through activation
of thehexosamine biosynthetic pathway. In-vitro andanimal (mainly
rat) studies demonstrate that glucosamine induces insulin resistance
in a variety of tissues including adipose, muscle and liver5. Further-
more, glucosamine has been shown to decrease pancreatic insulin
secretion6e8. However, these studies used glucosamine concentra-
tions 10e500 times higher than would be achieved by usual oral
doses of glucosamine4 and so they may not be clinically relevant.
A reviewarticle from2006 evaluated the effect of glucosamine on
glucose control in humans2. Glucosamine did not consistently affect
glucose metabolism but since most of the studies were of short
duration and excluded diabetic subjects, an adverse effect could not
be excluded. Other review articles reached similar conclusions4,9,10.
However, none of these articles were systematic reviews. Further-
more, since these reviews were published, there have been several
additional studies evaluating the effect of glucosamine on glucoseublished by Elsevier Ltd. All rights reserved.
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exogenous glucosamine on glucose metabolism in humans we have
carried out a systematic reviewof the literature. Our reviewdoes not
separate out the different formulations of glucosamine with respect
to their effects on glucose metabolism.
Methods
Criteria for inclusion
Types of studies
All types of studies and trials of anymethodological quality were
included. Searches were limited to English-language articles.
Types of participants
Adults receiving glucosamine. There were no restrictions in age,
health, gender, body mass index (BMI) or disease comorbidities.
Types of intervention
All types of glucosamine and administration by any route.
Types of outcome measures
All measures of glucose metabolism were included with the
exception of single measurements of random or fasting glucose.
Criteria for exclusion
The following exclusion criteria were applied: (1) In-vitro
studies, (2) Animal studies, (3) Unpublished data.Table I
Multi-dose administration of glucosamine
Study Design
(comparator)
Subjects
N DM/IGT/HN BMI mean (range)
Almada
(2001)19
DBRCT (placebo) 15 DM¼ 0
IGT¼ 0
HN¼ 15 (100%)
x¼ 27.2 (22.8e31.6)
kg/m2
Scroggie
(2003)14
DBRCT (placebo) 34 DMII¼ 34 (100%)
IGT¼ 0
HN¼ 0
N/A
Yu (2003)15 Pre-post
(no comparator)
14 DM¼ 0
IGT¼ 5 (36%)
HN¼ 9 (64%)
7/14 BMI >27 kg/m2
7/14 BMI <27 kg/m2
Tannis (2004)6 DBRCT (placebo) 19 DM¼ 0
IGT¼ 0
HN¼ 19 (100%)
x¼ 25.5 (18.6e31.1)
kg/m2
Muniyappa
(2006)16
DBRCT; cross-over
(placebo)
40 DM¼ 0
IGT¼ 0
HN¼ 40 (100%)
Lean (n¼ 20):
x¼ 24.3 kg/m2
Obese (n¼ 20):
x¼ 34.2 kg/m2
Albert (2007)12 DBRCT;
cross-over
(placebo)
12 DMI¼ 2 (17%)
DMII¼ 10 (83%)
IGT¼ 0
HN¼ 0
x¼ 36.7 (26.8e46.6)
kg/m2
Pham (2007)11 Pre-post
(no comparator)
38 DM¼ 0
IGT*¼ 7 (18%)
HN¼ 31 (82%)
x¼ 29.1 (19.2e46.3)
kg/m2
DBRCT¼Double-Blind Randomized Controlled Trial; N/A¼Not available; IGT¼ Impai
DMII¼ Type 2 Diabetes Mellitus; HN¼Healthy Normal; GS¼Glucosamine sulfate; GH¼G
FIRI¼ Fasting Insulin Resistance Index; IVGTT¼ Intravenous Glucose Tolerance Test; OG
Clamp; e¼No effect on glucose metabolism.
* This study documented increased fasting serum insulin levels (not impaired glucoseSearch strategy and study identiﬁcation
The following electronic data sourceswere systemically searched:
MEDLINE (1950eFebruary 2009), EMBASE (1980eFebruary 2009),
EMBASE Classic (1947e1979) and EBM Reviews (1991eFebruary
2009). Reference lists of all retrieved articles were also manually
searched to identify additional trials. All searches were updated in
February2009. The search strategyused inMEDLINE is shownbelow:
(1) Glucosamine
(2) Blood glucose
(3) Glucose metabolism
(4) Insulin resistance
(5) 1 and (2 or 3 or 4)
(6) Limit 5 to (English language andhumans andyr¼ “1950e2009”).
A total of 11 studies were included in this systematic
review6,11e20 (Tables I and II). Ten of the trials were indexed in
MEDLINE. No additional studies were indexed in EMBASE,
EMBASE Classic or EBM Reviews. One additional trial was iden-
tiﬁed by searching reference lists of previously published
reviews19.
Twenty-seven articles were excluded from this review (Fig. 1).
Twenty-four of these did not meet one or more of the inclusion
criteria2,4,5,9,10,21e37. Most were review articles or did not admin-
ister glucosamine or assess glucose metabolism. One article was
a non-English publication37, one was an animal study36 and one
was an in-vitro study38.Glucosamine Main outcomes Effect on glucose metabolism
Oral GS 1500 mg
OD 12 weeks
 Fasting glucose
 Fasting insulin
 FIRI
Decreased insulin sensitivity
(fasting insulin; FIRI)
Oral GH 1500 mg
OD 90 days
 HbA1c e
; Oral GS 1500 mg
OD 4 weeks
 Fasting glucose
 Fasting insulin
 “Meal tolerance
test”
 IVGTT
e
Oral GS 1500 mg
OD 12 weeks
 Fasting glucose
 Fasting insulin
 OGTT (3 h)
 HbA1c
e
Oral GH 1500 mg
OD 6 weeks
 Fasting glucose
 Fasting insulin
 HbA1c
 QUICKI
 Clamp
e
Oral, type N/A, 1500
mg/day 2 weeks
 Fasting glucose
 Fructosamine
e
Oral, type N/A 1500
mg/day 6 weeks
 Fasting glucose
 Fasting insulin
 HbA1c
 HOMA/QUICKI
Decreased insulin
sensitivity
(HOMA/QUICKI)
red Glucose Tolerance; DM¼Diabetes Mellitus; DMI¼ Type 1 Diabetes Mellitus;
lucosamine HCl; OD¼Daily; QUICKI¼Quantitative Insulin Sensitivity Check Index;
TT¼Oral Glucose Tolerance Test; Clamp¼Hyperinsulinemic-isoglycemic Glucose
tolerance).
Table II
Single dose administration of glucosamine
Study Design
(comparator)
Subjects Glucosamine Main outcomes Effect
N DM/IGT/HN BMI mean (range)
Monauni
(2000)17
RCT; cross-over
(placebo)
10 DM¼ 0
IGT¼ 0
HN¼ 10 (100%)
x¼ 23.5 (22e25)
kg/m2
IV, type N/A.
1.6 Umol/min/kg 300 min (all)
5 Umol/min/kg 300 min (n¼ 5)
 Fasting glucose
 IVGTT
 Clamp
 Fasting insulin
Increased fasting glucose;
Decreased insulin
sensitivity (IVGTT)
Pouwels
(2001)20
Control
(placebo)
20 DM¼ 0
IGT¼ 0
HN¼ 20 (100%)
x¼ 22.3 (20.4e24.2)
kg/m2
IV GS 4 Mmol/dL 150 min (n¼ 6)
or 300 min (n¼ 6)
Remaining 8 subjects placebo
 Fasting glucose
 Fasting insulin
 Clamp
e
Laferrere
(2004)18
Control
(no placebo)
20 DM¼ 0
IGT¼ 0
HN¼ 20 (100%)
x¼N/A (20.8e29.5)
kg/m2
Oral GS 3000 mg 1 dose (n¼ 6)
Oral GS 6000 mg 1 dose (n¼ 5)
Remaining nine subjects control
(no glucosamine)
 Fasting glucose
 Fasting insulin
 Leptin
e
Biggee
(2007)13
Control;
cross-over
(placebo)
16 DM¼ 0
IGT¼ 3 (19%)*
HN¼ 13 (81%)
x¼ 31 (22e40)
kg/m2
Oral GS 1500 mg X1 dose  Fasting glucose
 Fasting insulin
 Random insulin
 OGTT (2 and 3 h)
Decreased insulin
sensitivity in subjects
with IGT/DM (OGTT)
* Three subjects reported to have previously undiagnosed DM or IGT.
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A data extraction form, modiﬁed from the form used in
a previous review evaluating OA of the hand, was used to extract
information pertaining to trial demographics, methodology, quality
and outcomes39. For the studies that were randomized controlled
trials (RCTs), the Jadad score was calculated to evaluate the study
quality40,41. All studies were independently assessed by two
authors (ND and TET) and data extraction forms were compared for
disagreements.
Results
Overview of study demographics
A total of 11 studies were analyzed6,11e20 (Tables I and II).
Seven of the 11 studies administered multiple doses of
glucosamine (1500 mg orally per day, usually in three divided
doses). These studies ranged between 2 and 12 weeks. One
study also administered chondroitin (1200 mg per day)14. The
other four studies administered single doses of glucosamine.
Two used oral glucosamine (1500e6000 mg)13,18 and two used
intravenous glucosamine infusions (7.2e30.5 g total)4,17,20. The
average number of subjects was 21.6 with a range of 10e40
subjects. All of the studies were published between 2000 and
2007.38 potentially relevant articles reviewed 
27 articles exclud
 16 –  revie
 5 –  no me
 3 – did no
1 –  in-vit
 1 –  anima
 1 –  article
11 articles included in systematic review 
Fig. 1. Study selection foSix studies administered glucosamine sulfate, two administered
glucosamine hydrochloride and three did not report the type of
glucosamine used.
Six of the studies were RCTs6,12,14,16,17,19, three were non-
randomized controlled trials13,18,20 and the remaining two used
a pre-post design11,15. The six RCTs had a mean Jadad score of 3.7
(range 2e5).
Two of the studies used diabetic subjects. All the subjects in the
study by Scroggie et al. had type 2 diabetes14 while the study by
Albert et al. included both type 1 and 2 diabetes12. Three of the
studies included subjects with impaired glucose tolerance or insulin
resistance, although they onlymade up aminority (37%) of subjects
within those studies11,13,15. The remaining six studies did not include
any subjects with diabetes or impaired glucose tolerance.
Themajorityof the studies includedobese subjects. In sevenof the
studies, the average BMI was >25 kg/m2. Two studies did not have
any obese subjects17,20 and two studies did not report BMI14,18.
Many different tests of glucose metabolismwere used (Table III).
The most common were fasting glucose (10 studies) and fasting
insulin (nine studies). Other less commonly used tests included
fructosamine and vascular elasticity analysis11,16.
Effect on glucose metabolism
Four out of the 11 studies reported a signiﬁcant effect on glucose
metabolism11,13,17,19. Two of these studies administered multipleed 
w/comment (no new data) 
asurement of glucose metabolism 
t administer glucosamine 
ro 
l 
 not in English 
r systematic review.
Table III
Measurements of glucose metabolism and study outcome
Measurement of glucose
metabolism
# studies # demonstrating adverse
effect on glucose metabolism
Fasting glucose 10 0
Fasting insulin 9 1 (11%)
HbA1c 4 0
Oral glucose tolerance test 2 1 (50%)
Intravenous glucose tolerance test 3 2 (66%)
Composites of fasting glucose
and insulin*
3 2 (66%)
Hyperinsulinemic-isoglycemic
glucose clamp
3 0
* FIRI, QUICKI andHomeostasisModel Assessment of Insulin Resistance (HOMA-IR).
Table IV
Type of glucosamine and study outcome
Type of glucosamine # studies # reporting effect on
glucose metabolism
Sulfate 6 2 (33%)
Hydrochloride 2 0
Not reported 3 2 (66%)
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e one administered oral glucosamine13 and the other administered
an intravenous infusion17.
Of these four ‘positive’ studies, two included subjects with base-
line impaired glucose tolerance or insulin resistance (Fig. 2)11,13.
Neither of the two studies on diabetic subjects detected a statistically
signiﬁcant effect on glucose metabolism12,14. Three of the seven
studies that included obese subjects found an effect on glucose
metabolism11,13,19.
There was no clear relationship between the type of glucos-
amine used and the detection of an effect on glucose metabolism
(Table IV). Of the studies that reported an effect on glucose
metabolism, two used glucosamine sulfate13,19 and two did not
report the type of glucosamine11,17.
Two of the studies that detected an effect on glucose metabolism
were RCTs (Table V)17,19. The other two studies that found an effect
were non-randomized; Biggee et al. was a placebo-controlled cross-
over trial13 and Pham et al. employed a pre-post design with no
comparator11.
Glucose tolerance tests and composites of fasting glucose and
insulin were more likely to detect an effect on glucose metabolism
than hemoglobin A1C (HbA1c) or single measures of fasting glucose
or insulin (Table III).* Numbers above bars refer to the number of stu
divided by total number of studies in the specifi
†2 studies did not report BMI 
2/3
  4/9 
0/2
*
0%
20%
40%
60%
80%
Yes No Yes
Diabetic subjects Subje%
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Fig. 2. Association between subject characteristics (diabetes, impaired glucose toDiscussion
This systematic review included 11 studies that directly inves-
tigated the effect of exogenous glucosamine on glucose metabolism
in humans. The studies were small, of short duration and there was
considerable heterogeneity in terms of dose, route and duration of
glucosamine administration. Only four of the studies detected an
effect on glucose metabolism. Thus, additional studies are needed
in order to determine if exogenous glucosamine adversely affects
glucose metabolism in humans. Our ﬁndings are concordant with
the conclusions of four recent reviews2,4,9,10.
Two of the studies that detected an effect on glucosemetabolism
administered 1500 mg of glucosamine every day for 611 or 1219
weeks. The other two ‘positive’ studies used single doses of
glucosamine. Biggee et al. administered 1500 mg of oral glucos-
amine sulfate, which is the typical daily therapeutic dose13. The
subjects in the study by Monauni et al. received a supratherapeutic
dose of glucosamine by infusion17. The effect on glucosemetabolism
from this very large dose of parenterally administered glucosamine
is probably not applicable to patients using oral glucosamine.
In this study, we looked for possible relationships between the
detection of an effect on glucose metabolism and subject charac-
teristics, type of glucosamine, study design and method of
measuring glucose metabolism. These relationships are compared
in Fig. 2 and Tables IIIeV.
As shown in Fig. 2, studies that included subjects with impaired
glucose tolerance or insulin resistanceweremore likely to detect an
effect on glucose metabolism than studies without those subjects.
However, in the two studies that detected an effect, such subjects
made up a small minority of total subjectse seven subjects (18%) indies showing an effect on glucose metabolism 
ed category 
3/7
1/2
2/8
No Yes No
cts with Impaired Glucose
Tolerance
Obese (Mean BMI
>25 or obese group)
†
lerance and obesity) and studies reporting an effect of glucose metabolism.
Table V
Study design and outcome
Type of study # studies # reporting effect on
glucose metabolism
RCT 6 2 (33%)
Non-randomized controlled trials 3 1 (33%)
Pre-post 2 1 (50%)
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(19%) in Biggee et al. had glucose intolerance13.
There were two studies that involved diabetic subjects. Scroggie
et al. found that HbA1c increased by 0.05% in subjects taking
glucosamine compared to a decrease of 0.16% in the placebo
group14. However, this difference was not statistically signiﬁcant.
The other study of diabetic subjects, Albert et al., similarly did not
ﬁnd a signiﬁcant difference in fasting glucose or fructosamine
between the glucosamine and placebo groups12.
Figure 2 also shows that there was no signiﬁcant difference
between the percentage of studies that included obese subjects
which detected an effect on glucose metabolism (3/7 or 43%)11,13,19
compared to studies that excluded obese subjects (1/2 or 50%)17.
There was no clear association between the type of glucosamine
used and studies demonstrating an effect on glucose metabolism
(Table IV). In addition to the type of glucosamine (sulfate or hydro-
chloride), the brand may also be important. In the Cochrane review,
only glucosamine made by Rottapharm was shown to signiﬁcantly
improve pain and functional limitations in OA patients1. This implies
that pharmacological properties, including effect on glucose
metabolism, could differ between brands. Unfortunately, six of the
studies did not state which brand of glucosamine was used.
However, in the two studies that used glucosamine from
Rottapharm13,20 one foundaneffectonglucosemetabolism13 and the
other did not, suggesting that this particular brand does not appear
to be unique in terms of producing an effect on glucosemetabolism.
As shown in Table V, there was no association between the type
of study design and the ability to observe an effect on glucose
metabolism. The six RCTs were overall of good methodological
quality, with an average Jadad score of 3.7/5. The RCT by Almada
et al. is only published in abstract format19. The Jadad score was
designed to evaluate full-length manuscripts and so may be of less
value in the appraisal of an abstract. When the RCT by Almada et al.
is not included, the average Jadad score of the remaining ﬁve RCTs is
essentially unchanged (3.8/5).
Multiple tests of glucose levels were used (Table III). As expec-
ted, more sensitive measures such as glucose tolerance tests or
composites of fasting insulin and glucoseweremore likely to detect
an effect on glucose levels than less sensitive measures such as
single measures of fasting glucose or insulin. However, the gold
standard for assessing insulin resistance, the hyperinsulinemic-
isoglycemic glucose clamp, did not detect an effect on glucose
metabolism in any of the three studies in which it was used16,17,20.
Over the last decade there have been several large RCTs evalu-
ating the efﬁcacy of oral glucosamine for the treatment of OA42e45.
These studies ranged between 6 months and 3 years in duration
and included a combined total of over 2000 subjects. Unfortunately,
they could not be included in this systemic review since they only
measured random glucose43, did not specify if they actually
assessed glucose metabolism45 or did not provide values for
measures of glucose metabolism42,44,45. Notably, none of these
studies reported an adverse effect on glucose metabolism among
subjects taking glucosamine. This suggests that glucosamine likely
does not have a major effect on glucose metabolism. However,
a minor effect cannot be ruled out since they were not designed to
appropriately assess glucose metabolism.A number of limitations of this systematic review are recog-
nized. First, we only included English-language publications.
Second, non-published data were excluded, and this may have
resulted in a biased selection of trials, which were more likely to
include positive trials. Third, although conference abstracts were
included19, conference proceedings were not manually searched.
It is clear from this review that further research is required,
particularly involving subjects with impaired glucose tolerance and
insulin resistance, before we can determine if glucosamine has an
adverse effect on glucose metabolism in humans.
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